Prognostic Implication of Metabolic Syndrome in Patients with Nasopharyngeal Carcinoma: A Large Institution-Based Cohort Study from an Endemic Area

Abstract

Shengyan Huang,1,* Xirong Tan,1,* Ping Feng,1,2,* Sha Gong,1 Qingmei He,1 Xunhua Zhu,1 Na Liu,1 Yingqing Li1 1State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy; Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yingqing Li; Na Liu Tel [phone]Fax [phone]Email [email protected]; [email protected]: Metabolic syndrome has been identified as a prognostic predictor in multiple cancers. This study aimed to evaluate the impact of metabolic syndrome on the clinical outcome of patients with nasopharyngeal carcinoma (NPC) and its mechanism.Methods: A cohort of 2003 NPC patients with a median follow-up time of 96.3 months (range: 4.1– 120.0 months) were enrolled in this analysis. Kaplan–Meier curves and the Log rank test were used to determine the differences in progression-free survival (PFS), cancer specific survival (CSS) and overall survival (OS). Univariate and multivariable analyses were used to identify independent prognostic predictors. Untargeted metabolomics (LC-HRMS) was used to detect the serum metabolic profiles of 10 well-matched patients with or without metabolic syndrome. Differential metabolite-based enrichment analysis and pathway analysis were performed to identify the potential mechanism of metabolic syndrome in NPC.Results: A total of 171/2003 (8.5%) patients were diagnosed with metabolic syndrome, and these patients tended to be male (P 1 or log2 (FC)

Keywords

• nasopharyngeal carcinoma
• metabolic syndrome
• metabolite
• prognosis
• survival